Weyerhaeuser Co. (WY) had a light trading with around 4.17M shares changing hands compared to its three month average trading volume of 4.29M. The stock traded between $32.97 and $33.57 before closing at the price of $33.29 with -1.48% change on the day. The Federal Way Washington 98003 based company is currently trading 53.08% above its 52 week low of $22.35 and -2.09% below its 52 week high of $34. Both the RSI indicator and target price of 63.81 and $34.46 respectively, lead us to believe that it should be put on hold over the coming weeks.
Weyerhaeuser Co. is a real estate investment trust. It primarily invests in United States. The firm operates under four business segments, timberlands, wood products, cellulose fibers and real estate. It owns timberlands primarily in the U.S and has long-term licenses in Canada. The firm manufactures wood and specialty cellulose fibers products, and develops real estate, primarily as a builder of single-family homes. Weyerhaeuser Co was founded in 1900 and is based in Seattle, Washington.
Red Hat, Inc. (RHT) continued its upward trend with the stock climbing 0.4% or $0.32 to close the day at $80.09 on light trading volume of 1.31M shares, compared to its three month average trading volume of 1.92M. The Raleigh North Carolina 27601 based company has been outperforming the application software group over the past 52 weeks, with the stock gaining 25.45%, compared to the industry which has advanced 29.41% over the same period. With RSI of 66.08, the stock should still continue to rise and get closer to its one year target estimate of $86.2, making it a hold for now.
Red Hat, Inc. provides open source software solutions to develop and offer operating system, virtualization, management, middleware, cloud, mobile, and storage technologies to various enterprises worldwide. It offers infrastructure-related solutions, such as Red Hat Enterprise Linux, an operating system platform that runs on hardware for use in physical, virtual, container, and cloud environments; Red Hat Satellite, a system management offering that helps to deploy and manage Red Hat infrastructure across physical and virtual servers, and cloud environments; and Red Hat Enterprise Virtualization, a software solution that allows customers to utilize and manage a common hardware infrastructure to run multiple operating systems and applications. The company offers application development-related and other technology solutions, such as Red Hat JBoss Middleware, a solution for developing, deploying, and managing applications, as well as integrating applications, data, and devices along with business processes automation; Red Hat cloud offerings, a software solution that enables customers to build and manage various cloud computing environments; Red Hat Mobile, a software development platform that enables customers to develop, integrate, deploy, and manage mobile applications for enterprises; and Red Hat Storage, a software solution that enables customers to treat physical server storage as a scalable, shared, centrally-managed pool of virtual storage and to manage large, unstructured, or semi-structured data in physical, virtual, and cloud environments. It also provides consulting, support, and training services; and real-time operating system, distributed computing, directory services, and user authentication. The company was formerly known as Red Hat Software, Inc. and changed its name to Red Hat, Inc. in June 1999. Red Hat, Inc. was founded in 1993 and is headquartered in Raleigh, North Carolina.
Abbott Laboratories (ABT) shares were up in last trading by 0.99% to $43.65. It experienced lighter than average volume on day. The stock increased in value by almost 1.77% over the past week and grew 6.65% in the past month. It is currently trading 9.27% above its 50 day moving average and 8.66% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -3.45% decrease in value from its one year high of $45.79. The RSI indicator value of 76.02, lead us to believe that it may reverse gains in the near term.
Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.